Free Trial

Champions Oncology Q4 2023 Earnings Report

Champions Oncology EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Champions Oncology Revenue Results

Actual Revenue
$11.57 million
Expected Revenue
$12.62 million
Beat/Miss
Missed by -$1.05 million
YoY Revenue Growth
N/A

Champions Oncology Announcement Details

Quarter
Q4 2023
Time
After Market Closes

Champions Oncology Earnings Headlines

“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Champions Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Champions Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Champions Oncology and other key companies, straight to your email.

About Champions Oncology

Champions Oncology (NASDAQ:CSBR) engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

View Champions Oncology Profile

More Earnings Resources from MarketBeat